steer study semaglutide ESC 2025: cuts MACE risk by 57 perc ESC 2025: Novo Nordisk's Wegovy
Description
Steady weight loss averaging 5-6 pounds per month
[3] Fiber also supports satiety and weight management
Both medications work by mimicking certain hormones in the bodys incretin system
Nadarajan et al., 2009
Semaglutide is a GLP-1 receptor agonist, originally developed to treat type 2 diabetes
For Research Use Only not for human or animal consumption
